Enanta Pharmaceuticals (ENTA) Research & Development (2012 - 2026)

Enanta Pharmaceuticals has reported Research & Development for 15 years, with the latest figure at $19.4 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development fell 30.72% year-over-year to $19.4 million; the trailing twelve-month figure through Mar 2026 stood at $91.3 million (down 20.76% YoY), and the FY2025 full-year result was $106.7 million, down 18.81% from the prior year.
• Research & Development for Q1 2026 stood at $19.4 million, down from $20.9 million in the prior quarter.
• The five-year high for Research & Development was $43.5 million in Q1 2023, with the low at $19.4 million in Q1 2026.
• Historically, Research & Development has averaged $32.8 million across 5 years, with a median of $34.8 million in 2022.
• Annual changes were most pronounced in 2023 — Research & Development grew 9.97% — and 2024, when it tumbled 33.14%.
• Enanta Pharmaceuticals' Research & Development stood at $40.9 million in 2022, then retreated by 11.08% to $36.4 million in 2023, then declined by 23.96% to $27.7 million in 2024, then slipped by 24.58% to $20.9 million in 2025, then dropped by 6.79% to $19.4 million in 2026.
• The last three Research & Development figures came in at $19.4 million (Q1 2026), $20.9 million (Q4 2025), and $23.8 million (Q3 2025), per Business Quant data.